<SEC-DOCUMENT>0000905148-25-002815.txt : 20250811
<SEC-HEADER>0000905148-25-002815.hdr.sgml : 20250811
<ACCEPTANCE-DATETIME>20250811165543
ACCESSION NUMBER:		0000905148-25-002815
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250811
DATE AS OF CHANGE:		20250811

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neumora Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001885522
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				844367680
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94162
		FILM NUMBER:		251202746

	BUSINESS ADDRESS:	
		STREET 1:		260 ARSENAL PLACE, SUITE 1
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(857) 760-0900

	MAIL ADDRESS:	
		STREET 1:		260 ARSENAL PLACE, SUITE 1
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RBNC Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210929

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			K2 HealthVentures Equity Trust LLC
		CENTRAL INDEX KEY:			0001948604
		ORGANIZATION NAME:           	
		EIN:				842128131
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		855 BOYLSTON STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		857-201-5983

	MAIL ADDRESS:	
		STREET 1:		855 BOYLSTON STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001948604</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>05/09/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001885522</issuerCik>
<issuerName>Neumora Therapeutics, Inc.</issuerName>
<issuerCusip>640979100</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>260 Arsenal Place</com:street1>
<com:street2>Suite 1</com:street2>
<com:city>Watertown</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02472</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>K2 HealthVentures Equity Trust LLC</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>11397310</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>11397310</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>11397310</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>6.6</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Parag Shah</reportingPersonName>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>11397310</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>11397310</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>11397310</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>6.6</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<typeOfReportingPerson>HC</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Anup Arora</reportingPersonName>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>11397310</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>11397310</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>11397310</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>6.6</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<typeOfReportingPerson>HC</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Neumora Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):&#13;
&#13;
i.	K2 HealthVentures Equity Trust LLC ("K2HV Equity");&#13;
ii.	Parag Shah ("Mr. Shah"); and&#13;
iii.	Anup Arora ("Mr. Arora").&#13;
&#13;
This Statement on Schedule 13G relates to shares of Common Stock K2HV Equity has the right to acquire within 60 days upon conversion of up to $10,000,000 of outstanding principal of the Issuer's outstanding debt obligations to K2HV Equity under a loan and security agreement the Issuer and K2HV Equity entered into on May 9, 2025, at a conversion price of the lesser of $0.8774 per share and the lowest effective price per share of the Issuer's next equity financing (the "Conversion Shares").  For purposes of this Schedule 13G, we have assumed a conversion price of $0.8774 per share, which results in the Reporting Persons beneficially owning approximately 11,397,310 shares of Common Stock&#13;
&#13;
K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it has the right to acquire upon conversion of the Conversion Shares, as reported herein.  Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116.</principalBusinessOfficeOrResidenceAddress>
<citizenship>K2HV Equity is a Delaware limited liability company.  Each of Mr. Shah and Mr. Arora is a citizen of the United States of America.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>As of May 9, 2025 and the date hereof, each of the Reporting Persons may be deemed the beneficial owner of 11,397,310 shares of Common Stock, which consist entirely of shares of Common Stock K2HV Equity has the right to acquire upon conversion of the Conversion Shares.</amountBeneficiallyOwned>
<classPercent>As of May 9, 2025 and the date hereof, each of the Reporting Persons may be deemed the beneficial owner of approximately 6.6% of the shares of Common Stock outstanding.&#13;
&#13;
The percentage set forth herein is calculated based on the sum of (i) 161,747,922 shares of Common Stock outstanding as of May 5, 2025 and 161,945,427 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's quarterly reports on Form 10-Q, filed with the Securities and Exchange Commission on May 12, 2025 and August 6, 2025, respectively, and (ii) 11,397,310 shares of Common Stock that are issuable to K2HV Equity within 60 days upon conversion of the Conversion Shares, which Conversion Shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>0</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>11,397,310</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>11,397,310</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<exhibitInfo>Exhibit 1: Joint Filing Agreement, dated August 11, 2025</exhibitInfo>
<signatureInformation>
<reportingPersonName>K2 HealthVentures Equity Trust LLC</reportingPersonName>
<signatureDetails>
<signature>/s/ Anup Arora</signature>
<title>Anup Arora, Managing Member</title>
<date>08/11/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Parag Shah</reportingPersonName>
<signatureDetails>
<signature>/s/ Parag Shah</signature>
<title>Parag Shah</title>
<date>08/11/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Anup Arora</reportingPersonName>
<signatureDetails>
<signature>/s/ Anup Arora</signature>
<title>Anup Arora</title>
<date>08/11/2025</date>
</signatureDetails>
</signatureInformation>
</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>jfa.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Sidley Austin LLP
         Document created using Broadridge PROfile 25.3.1.5296
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-weight: bold;">EXHIBIT 1</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">JOINT FILING AGREEMENT</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Neumora Therapeutics, Inc., dated as of August 11, 2025, is, and any amendments thereto (including
      amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z82dfb75eee5e4197b091af38128c9192">

        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>Dated: August 11, 2025</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div style="font-weight: bold;">K2 HEALTHVENTURES EQUITY TRUST LLC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 44.37%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td nowrap="nowrap" style="width: 44.37%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div>/s/ Anup Arora</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top;">
            <div>Anup Arora</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top;">
            <div>Managing Member</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div style="font-weight: bold;">PARAG SHAH</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div>/s/ Parag Shah</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td colspan="2" style="width: 50.64%; vertical-align: top;">
            <div style="font-weight: bold;">ANUP ARORA</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.36%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 6.27%; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 44.37%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div>/s/ Anup Arora</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="margin-top: 10pt;"><br>
    </div>
    <div style="margin-top: 10pt;"><br>
    </div>
    <div style="margin-top: 10pt;"><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="margin-top: 10pt;"><br>
    </div>
    <div style="margin-top: 10pt;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
